How much funding has Avid Radiopharmaceuticals raised?

Avid Radiopharmaceuticals has raised $69.9M in total funding, most recently a Series D round.

Who are Avid Radiopharmaceuticals's investors?

Avid Radiopharmaceuticals's investors include Alta Partners, Pfizer Ventures, AllianceBernstein, Safeguard Scientifics, Eli Lilly.

When was Avid Radiopharmaceuticals founded?

Avid Radiopharmaceuticals was founded in 2005.

Where is Avid Radiopharmaceuticals headquartered?

Avid Radiopharmaceuticals is headquartered in Philadelphia, Pennsylvania, United States.

What industry is Avid Radiopharmaceuticals in?

Avid Radiopharmaceuticals operates in Biotech, Healthcare.

How many employees does Avid Radiopharmaceuticals have?

Avid Radiopharmaceuticals has 51-200 employees.

Avid Radiopharmaceuticals

Acquired

Philadelphia, United States · Founded 2005 · $69.9M raised

Biotech

Healthcare

Headquarters: Philadelphia, Pennsylvania
Employees: 51–200
Founded: 2005
Business Model: B2B

Website: avidrp.com
Total Funding: $69.9M
Last Round: $34.5M Series DMay 2009
Rounds: 4

About

Avid Radiopharmaceuticals is a Philadelphia-based molecular imaging company founded in 2005 and acquired by Eli Lilly in 2010, operating as a wholly-owned subsidiary. The company's mission is to discover, develop, and deliver diagnostic solutions that improve global health by accelerating the development of new medicines. Avid is best known for developing Amyvid (florbetapir F 18 injection), the first FDA-approved PET imaging agent for detecting amyloid plaques associated with Alzheimer's disease. Based at the University City Science Center research campus in Philadelphia, the company focuses on radiopharmaceutical diagnostics to advance neuroscience and other disease areas.

Summary

Avid Radiopharmaceuticals is a Biotech company based in Philadelphia, United States, founded in 2005. It has raised $69.9M in total across 4 rounds, most recently a $34.5M Series D round in May 2009. Investors include Alta Partners, Pfizer Ventures and AllianceBernstein.